georgie18
3年前
RGRX...16...Bullish Harami Cross Reversal Pattern formed to the Upside as the Bollies start to Squeeze...
RGRX...Looking for RGRX to Break the .16/.20 Consolidation Channel to the Upside and make a run at the previous high of .82 should they have positive news from the FDA meeting...imo...we shall see...
Chart... https://schrts.co/cbFeWPua ...
Will be adding more for the February FDA meeting...
ROCKVILLE, Md., Dec. 17, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the U.S. FDA has accepted its request for a pre-BLA meeting pursuant to RGN-259, its novel product candidate for dry eye syndrome. The meeting is scheduled for February 28, 2022. A BLA (Biologics License Application) is FDA's standard "full approval" mechanism for biological products, including therapeutics and vaccines.
georgie18
3年前
RGRX...1675...Bullish Harami Cross Reversal Pattern to the Upside on this Oversold Williams...adding on this Pattern...
Chart...https://schrts.co/XgYaVXyM ...
Authorized Shares
200,000,000
10/18/2021
Outstanding Shares
143,549,735
10/18/2021
Held at DTC
71,886,334
10/18/2021
Float
69,090,013
08/31/2021
All City Baby
4年前
GTRIBNT completes phase 3 clinical trial for dry eye syndrome (ARISE-3) data lock-up
By GtreeBNT 2021 years 2 24-days Mon. - , Press Releases
GTRIBNT (115450) is a data lock-up that prevents modification of all numbers and information of clinical data conducted at 20 hospitals across the United States for ARISE-3, phase 3 clinical trial of dry eye treatment (RNG-259). It was announced on the 24th that it was completed.
A GTRIBNT official said, "We have completed data cleaning, which is the current ARISE-3 clinical data cleanup task, and have completed Data Lock-Up to confirm and collect clinical data in 20 US hospitals." As soon as the statistical analysis of variables as well as all endpoints in the protocol is completed, the results will be disclosed in Korea and the United States, especially as some multinational companies are already waiting for the results of ARISE-3 I will derive data.”
GTRIBNT has already secured major intellectual property rights such as patents for compositions and pharmaceutical formulations, and patents for manufacturing method of eye drops for future market monopoly along with the progress of phase 3 clinical trials related to the development of new dry eye drugs, as well as the US FDA. As the product approval process is divided into a biologics license application (BLA), a 12-year monopoly on the new drug market can be granted upon approval.
Meanwhile, in a report published in June 2020 regarding the dry eye treatment market,'Global Data', an overseas analysis agency, predicts the dry eye treatment market in 9 countries, including the United States, at 13 trillion won. Compared to Zydra, Gtree B&T's RGN-259 is predicted to have the largest cumulative sales from 2022 to 2028, as it has a competitive edge in that it has no discomfort such as a burning sensation and rapid drug expression.
https://lveulxwbijija56pkhqkk4tgee-adwhj77lcyoafdy-gtreebnt-com.translate.goog/2021/02/24/%ec%a7%80%ed%8a%b8%eb%a6%ac%eb%b9%84%ec%95%a4%ed%8b%b0-%ec%95%88%ea%b5%ac%ea%b1%b4%ec%a1%b0%ec%a6%9d-%ec%b9%98%eb%a3%8c%ec%a0%9c-%ec%9e%84%ec%83%81-3%ec%83%81arise-3-data-lock-up-%ec%99%84%eb%a3%8c/
georgie18
4年前
RGRX...69...Looking for the Break/Hold of the Resistance Neckline on the Cup N Handle Continuation Pattern...imo...we shall see...
georgie18 Monday, 01/11/21 04:51:43 AM
Re: georgie18 post# 311 0
Post #
316
of 324
RGRX...46...Long Term Cup N Handle Contiuation Pattern setting up here...Waiting for the right side of the hanlde to form...Confirmation at the Break/Hold of .75 range Resistance Neckline...Adding to my core position here...
Target...$1.40 range...Deduct the bottom .10 range from the Resistance Neckline .75 range =.65 range then add the difference to the Resistance Neckline .75range = $1.40 range...
Chart...https://schrts.co/MDyrYxZg
georgie18 Saturday, 12/19/20 01:03:21 PM
Re: None 0
Post #
311
of 315
RGRX...3750...Oversold Pincher play...Pincher Squeezing real hard here setting up the breakout...imo...we shall see...
Chart...https://schrts.co/egkHdUYy
Authorized Shares
200,000,000
12/02/2020
Outstanding Shares
133,441,788
12/02/2020